

Jenny Bulgarelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5530695/publications.pdf>

Version: 2024-02-01

27
papers

405
citations

933447

10
h-index

794594

19
g-index

28
all docs

28
docs citations

28
times ranked

960
citing authors

#	ARTICLE	IF	CITATIONS
1	The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation. <i>Haematologica</i> , 2013, 98, 1115-1123.	3.5	92
2	MYB controls erythroid versus megakaryocyte lineage fate decision through the miR-486-3p-mediated downregulation of MAF. <i>Cell Death and Differentiation</i> , 2015, 22, 1906-1921.	11.2	60
3	Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia. <i>Haematologica</i> , 2015, 100, 253-262.	3.5	40
4	Endothelin-1 Promotes Survival and Chemoresistance in Chronic Lymphocytic Leukemia B Cells through ETA Receptor. <i>PLoS ONE</i> , 2014, 9, e98818.	2.5	33
5	<i>ANGPT2</i> promoter methylation is strongly associated with gene expression and prognosis in chronic lymphocytic leukemia. <i>Epigenetics</i> , 2013, 8, 720-729.	2.7	30
6	Physical contact with endothelial cells through $\alpha 1$ - and $\alpha 2$ - integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells. <i>Haematologica</i> , 2012, 97, 952-960.	3.5	29
7	Clinical heterogeneity of <i>de novo</i> 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone. <i>Hematological Oncology</i> , 2013, 31, 88-95.	1.7	25
8	Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia. <i>Experimental Hematology</i> , 2014, 42, 126-136.e1.	0.4	23
9	Dendritic Cell Vaccination in Metastatic Melanoma Turns α Non-T Cell Inflamed α Into α T-Cell Inflamed α Tumors. <i>Frontiers in Immunology</i> , 2019, 10, 2353.	4.8	22
10	Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience. <i>Melanoma Research</i> , 2017, 27, 351-357.	1.2	14
11	Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide. <i>Leukemia and Lymphoma</i> , 2018, 59, 423-433.	1.3	7
12	Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 29		
13	Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 778459.	4.8	6
14	Effects of a Diet Based on Foods from Symbiotic Agriculture on the Gut Microbiota of Subjects at Risk for Metabolic Syndrome. <i>Nutrients</i> , 2021, 13, 2081.	4.1	5
15	Skewing effect of sulprostone on dendritic cell maturation compared with dinoprostone. <i>Cytotherapy</i> , 2018, 20, 851-860.	0.7	3
16	Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose interleukin-2: Interim analysis data.. <i>Journal of Clinical Oncology</i> , 2015, 33, e14007-e14007.	1.6	3
17	Stability Program in Dendritic Cell Vaccines: A α Real-World α Experience in the Immuno-Geno Therapy Factory of Romagna Cancer Center. <i>Vaccines</i> , 2022, 10, 999.	4.4	3
18	In Vitro and in Vivo Evidence of an Anti-Angiogenic Effect of Lenalidomide in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 1782-1782.	1.4	2

#	ARTICLE	IF	CITATIONS
19	Abstract 2776: Sequential immunohistochemistry and computational image analysis for a deeper characterization of tumor-infiltrating myeloid cells. , 2021, , .		0
20	381TiP Vaccination with autologous dendritic cells loaded with autologous tumour homogenate in resected glioblastoma: A phase II study (CombiGVax). Annals of Oncology, 2021, 32, S529.	1.2	0
21	A Prospective, Multi Center Phase II Study Evaluating Predictive Factors for Lenalidomide Treatment in Relapse or Refractory Chronic Lymphocytic Leukemia Patients (LE.P.RE.): Preliminary Results about the First 20 Enrolled Patients. Blood, 2011, 118, 1782-1782.	1.4	0
22	Lenalidomide Promotes a Pro-Inflammatory Switch of Nurse-like Cells Derived from Chronic Lymphocytic Leukemia. Blood, 2014, 124, 3286-3286.	1.4	0
23	C-Myb Restrains Megakaryopoiesis through the Hsa-MiR-486-3p-Driven Down-Regulation of C-Maf. Blood, 2014, 124, 5124-5124.	1.4	0
24	The ACC melanoma pilot project: "Real-world" evaluation of an NGS platform for molecular characterization of melanoma in Italy.. Journal of Clinical Oncology, 2019, 37, e14600-e14600.	1.6	0
25	Radiotherapy as an Immunological Booster in Patients with Metastatic Melanoma or Renal Cell Carcinoma Treated with High-Dose Interleukin-2: Final Data. Annals of Oncology, 2019, 30, xi44-xi45.	1.2	0
26	49P A phase II randomized trial with adjuvant autologous tumor lysate-pulsed dendritic cells (DC) in resected stage III-IV melanoma patients: Preliminary immunological results. Annals of Oncology, 2021, 32, S1394.	1.2	0
27	832"Unravelling human melanoma heterogeneity by 6-color multiplex immunofluorescence to overcome recurrence and resistance to therapy. , 2020, , .		0